INTRODUCTION
STUDY GOALS AND OBJECTIVES
This BCC Research report, Biological Therapies for Cancer: Technologies and Global Markets, provides a detailed overview and thorough analysis of the present and future global market for cancer biotherapeutics. This report analyzes in detail the biological cancer markets. This report includes products in this market, and detailed analyses of markets and competitive environments, cancer markets in newly emerging therapeutics, and biosimilars and their impact on the market. The report includes information about significant products, key players, issues and trends, current market status of cancer biotherapeutics, strengths, weaknesses, opportunities and threats facing various cancer biotherapeutics already on the market, major issues involved in the research and development (R&D) of more effective cancer therapeutics, and new cancer therapeutics in development and in clinical trials.
REASONS FOR DOING THE STUDY
The rise in the number of cancer diagnosis, wider access, and affordability of treatment regimes in developing countries will stimulate growth in the world cancer therapies market. It is the second-leading cause of death in the U.S. and according to the American Cancer Society (ACS), 50% of men and 30% of women will develop some form of cancer in their lifetime. Newer biotherapeutics have emerged in the past few years that have had a significant impact on cancer treatment and health. The market for biological therapies in cancer treatment will nearly double in the next 5 years and reach more than $50 billion in the next 5 to 10 years. The demand for newer and innovative oncology drugs will continue to grow as healthcare systems worldwide emphasize cancer detection and treatment. This report covers the current market status of cancer biotherapeutics, strengths, weaknesses, various cancer biotherapeutics already on the market, major issues involved in the R&D of more effective cancer therapeutics, and new cancer therapeutics in development and in clinical trials
SCOPE OF REPORT
The proposed report will give an update on Biological Therapies for Cancer: Technologies and Global Markets. It will review global markets for biologic therapeutics for cancer and will forecast trends for use of biologics and cancer treatment through 2014. Important biologics, market share by type of cancer, products on the market and market share by company, statistical information for types of cancers prevalent worldwide, with special emphasis on the U.S. market. The report also includes current issues and trends affecting the industry, costs, and factors influencing demand will be discussed. The report covers, biological products in development, biological products in clinical trials, currently marketed and late-stage development biologic cancer products.
The market and sales data in 2008 provides once again strong support for the R&D paradigm shift to biologic treatment for cancer and within biologic toward human monoclonal antibodies (mAbs), vaccines, and interferons (IFNs). The following biologic drug classes will be discussed in this report with a special focus on cancer treatment:
- mAbs
- Vaccines
- Erythropoietin (EPO)
- Colony stimulating factors (CSFs)
- Interleukins (ILs) and IFNs
The following approaches to cancer therapeutics are excluded from this report: chemotherapy, alkylating agents, antimetabolites, cytotoxic agents, plant derivatives, and hormone therapy corticosteroids, hormone antagonists/antagonists aromatase inhibitors selective estrogen receptor modulators (SERMs), radiation therapy and adjunctive therapy. Biological therapies for treatment of other diseases will not be addressed in this report.
INTENDED AUDIENCE
This report is an exhaustive study on the worldwide biological cancer treatment market, giving crucial statistics and analysis on the prevalence of cancer, market structure, market size, key drug segments, important trends in technology development, major opportunities, and market shares of key players and drugs. This report may prove crucial for the firms or investors seeking investments in the concerned sector. Biological therapy (sometimes called immunotherapy, biotherapy, or biological response modifier [BRM] therapy) is a relatively new addition to the family of cancer treatments that also includes surgery, chemotherapy, and radiation therapy. Biological therapies use the body’s immune system, either directly or indirectly, to fight cancer or to lessen the side effects that may be caused by some cancer treatments.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to paid databases. The base year of the report is 2008, with forecast data provided through 2014. Historical, base year and forecast data are provided for each market segment of this report. Growth rates are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D, and current product growth, etc.
ANALYST CREDENTIALS
Usha Nagavarapu is an experienced pharmaceutical professional with business development experience. She has more than 10 years of preclinical, alliance management, discovery and technology development marketing experience. Her strong focus areas include oncology and cardiovascular diseases, with expertise in molecular and cell biology and complex cell-based biological assays ranging from drug discovery, in-vitro and in-vivo screening, in-vivo model development, and pharmacokinetics. She has experience working with early start-ups.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers
DISCLAIMER
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
Report Code: BIO048B, Published: April 2010, Analyst: Usha Nagavarapu
